↓ Skip to main content

Methotrexate as a steroid sparing agent for asthma in adults

Overview of attention for article published in Cochrane database of systematic reviews, July 1998
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source
wikipedia
1 Wikipedia page

Citations

dimensions_citation
76 Dimensions

Readers on

mendeley
49 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Methotrexate as a steroid sparing agent for asthma in adults
Published in
Cochrane database of systematic reviews, July 1998
DOI 10.1002/14651858.cd000391
Pubmed ID
Authors

Huw Richard H R Davies, Leslie LG Olson, Peter G Gibson

Abstract

Sustained oral corticosteroid use can lead to complications, so there is interest in identifying agents that can reduce oral steroid use in people with asthma. Methotrexate has attracted attention as a possible steroid sparing agent in patients with chronic oral steroid dependent asthma. The objective of this review was to assess the effects of adding methotrexate to oral corticosteroids in adults with stable asthma who are dependent on oral corticosteroids. The Cochrane Airways Group trials register and reference lists of identified articles were searched. Randomised trials of the addition of methotrexate compared with placebo in adult steroid dependent asthmatics. Duration of therapy needed to be at least 12 weeks. Trial quality was assessed and data extraction was carried out by two reviewers independently. Study authors were contacted for missing information. Ten trials involving a total of 185 people were included. Study design and quality, corticosteroid dosages and outcomes varied widely. There was a reduction in oral corticosteroid dose favouring methotrexate in parallel trials (weighted mean difference -4.1 mg per day, 95% confidence interval -6.8 to -1.3) and also in cross-over trials (weighted mean difference -2.9 mg per day, 95% confidence interval -5.9 to -0.2). There was no difference between methotrexate and placebo for forced expiratory volume in one minute (weighted mean difference 0.12 litre, 95% confidence interval -0.21 to 0.45). Hepatotoxicity was a common adverse effect with methotrexate compared to placebo (odds ratio 6.9, 95% confidence interval 3.1 to 15.5). Methotrexate may have a small steroid sparing effect in adults with asthma who are dependent on oral corticosteroids. However, the overall reduction in daily steroid use is probably not large enough to reduce steroid-induced adverse effects. This small potential to reduce the impact of steroid side-effects is probably insufficient to offset the adverse effects of methotrexate.

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 2 4%
Brazil 1 2%
Unknown 46 94%

Demographic breakdown

Readers by professional status Count As %
Unspecified 9 18%
Student > Master 9 18%
Student > Bachelor 9 18%
Other 5 10%
Student > Ph. D. Student 4 8%
Other 13 27%
Readers by discipline Count As %
Medicine and Dentistry 31 63%
Unspecified 10 20%
Nursing and Health Professions 3 6%
Agricultural and Biological Sciences 1 2%
Biochemistry, Genetics and Molecular Biology 1 2%
Other 3 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 October 2019.
All research outputs
#2,516,599
of 13,617,861 outputs
Outputs from Cochrane database of systematic reviews
#5,391
of 10,681 outputs
Outputs of similar age
#74,276
of 271,609 outputs
Outputs of similar age from Cochrane database of systematic reviews
#111
of 178 outputs
Altmetric has tracked 13,617,861 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,681 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,609 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 178 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.